The Genomic Era:
In recent years, genomic diagnostic and screening tests have been able to accurately identify targeted treatments for cancer patients.
The tests lay the foundation for precision medicine, also called personalised or targeted medicine.
As a bonus: pharmacogenomic tests can determine whether the patient can metabolise (digest/absorb) the identified target treatment successfully.
These two tests have revolutionised cancer medicine with targeted treatments achieving better outcomes with minimal side effects.
Cancer patients now have a choice between the old and new cancer technologies...
Despite recent advances, the outdated one size fits all model is still common in conventional medicine as well as complementary & alternative cancer medicines.
One size fits all approaches are commonplace in…
Our hospitals – this is the Gold Standard of Cancer Care. Hospitals are limited by finances and hospital/insurance company protocols)
Supplements, super-foods or extreme diet approaches – the outdated assumption that certain diet regimes are good for all cancer patients.
Any generic advice from Dr Google, family, friends, workmates is by nature, one size fits all, and may do more harm than good, can cause cancer.
From Genome Mag – “Most often today, your treatment plan isn’t about you specifically.
It’s what doctors would give to anyone with the same condition — your neighbour, the hot dog vendor, or the prime minister of Bangladesh.
Most cancer medicine revolves around “standards of care,” that is providing the best courses of prevention or treatment for the average person on the street.
With breast cancer, for example, those standards mean self-exams and mammograms after a set age and the usual chemotherapy, surgery to treat a tumour if one is found.
If the first treatment doesn’t work, doctors and patients move on to the next one and the next. It’s trial and error, with life on the line.
But each cancer in each person has its own genetic makeup – each tumour is a unique character with unique tendencies and vulnerabilities.
In some cases, the current standard of care may be the safest, most sensible option, but it’s also one size fits all.
Sometimes that’s sufficient, but not always.”
Click here for detailed information about the unpredictability of side-effects associated with drug based immune therapies such as Keytruda and and Car T Cell Therapies
Testimonial to the new cancer technologies.
The patient, Jeffrey Deslandes, with cancer navigator Grace Gawler, (below) is a 12 year survivor of stage IV non-Hodgkin’s lymphoma.
Jeffrey is cancer free because he researched and embraced cancer vaccines delivered by a doctor in Brisbane. Impressed by his results, we referred patients to this doctor until he lost his research funding.
It was worth persevering with: We now help our patients access advanced cancer vaccines via our oncology colleagues in Japan (the Brisbane Dr trained in Japan).
Outcomes have been exceptional for most of our patients.
The cancer vaccines (immune therapies) are even more effective when used in conjunction with other high-tech treatments.
These include hyperthermia, low-dose radiation, Gamma knife, Cyber Knife, Proton Beam Therapy and even surgery.
Main points of difference between drug based and cell based immune therapies:
It is important to understand the difference in these immune therapies to those being used throughout the world.
The blood and tumour blood based immune therapies are very different to the drug based immune therapies made by big pharmaceutical companies.
Drug based immune therapies, while achieving some exceptional outcomes for some cancers, have unpredictable and severe side effects – often much worse than chemotherapy.
On the other hand, blood based immune therapies are predictable, have been used with over 10,000 patients and have minimal or no side effects
Don't miss out on the biggest breakthroughs in cancer medicine for decades. The following videos explain cancer genomics in layman's terms..
A bad deal for Australian Patients
As you can see, countries like Australia, Canada or New Zealand lag behind other OECD countries.
Via our global cancer navigation service, we can often access these medicines for our patients once they are approved overseas – sometimes this can be many years before available in Australia for example.
As well, we can help our patients access precision or personalised medicine built around genomic and pharmaco-genomic tests.
Our testimonial page (orange button below) features 10 quite remarkable patient stories – all were recipients of precision or personalised medicine.